Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II capecitabine + cisplatin in advanced head and neck cancer
2006-003775-13Phase 2Completed
- Sponsor
- Oncology Institute of Bari
- Start
- Oct 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and cisplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Oncology Institute of Bari. Primary endpoint: Safety of capecitabine + cisplatin. Started Oct 2006; status: completed.
02
Drugs
capecitabinecisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2006-003775-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003775-13.